Yong-Lian Zhu
Overview
Explore the profile of Yong-Lian Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Z, Al Zouabi N, Xu M, Bowen N, Wu T, Lavi E, et al.
Sci Rep
. 2021 Apr;
11(1):8042.
PMID: 33850183
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration...
2.
Lin Z, Zhu Y, Lo Y, Moscarelli J, Xiong A, Korayem Y, et al.
PLoS One
. 2018 Nov;
13(11):e0207399.
PMID: 30444904
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging....
3.
Lin Z, Zhu Y, Ratner E
Front Oncol
. 2018 Aug;
8:303.
PMID: 30135856
Ovarian, uterine/endometrial, and cervical cancers are major gynecologic malignancies estimated to cause nearly 30,000 deaths in 2018 in US. Defective cell cycle regulation is the hallmark of cancers underpinning the...
4.
Ishiguro K, Zhu Y, Lin Z, Penketh P, Shyam K, Zhu R, et al.
J Transl Sci
. 2016 Apr;
2(2):117-124.
PMID: 27076919
Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines...
5.
Ratner E, Zhu Y, Penketh P, Berenblum J, Whicker M, Huang P, et al.
Br J Cancer
. 2016 Mar;
114(7):777-86.
PMID: 26964031
Background: Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) in epithelial ovarian cancer (EOC). The objective of this study was to evaluate the...
6.
Shyam K, Penketh P, Baumann R, Finch R, Zhu R, Zhu Y, et al.
J Med Chem
. 2015 Jan;
58(9):3639-71.
PMID: 25612194
1,2-Bis(sulfonyl)-1-alkylhydrazines (BSHs) were conceived as more specific DNA guanine O-6 methylating and chloroethylating agents lacking many of the undesirable toxicophores contained in antitumor nitrosoureas. O(6)-Alkylguanine-DNA alkyltransferase (MGMT) is the sole...
7.
Ishiguro K, Lin Z, Penketh P, Shyam K, Zhu R, Baumann R, et al.
Biochem Pharmacol
. 2014 Aug;
91(3):312-22.
PMID: 25130544
Triapine, currently being evaluated as an antitumor agent in phase II clinical trials, and its terminally dimethylated derivative Dp44mT share the α-pyridyl thiosemicarbazone backbone that functions as ligands for transition...
8.
Ishiguro K, Zhu Y, Shyam K, Penketh P, Baumann R, Sartorelli A
Biochem Pharmacol
. 2010 Jul;
80(9):1317-25.
PMID: 20654586
O(6)-Alkylguanine-DNA alkyltransferase (AGT) mediates tumor resistance to alkylating agents that generate guanine O(6)-chloroethyl (Onrigin™ and carmustine) and O(6)-methyl (temozolomide) lesions; however, the relative efficiency of AGT protection against these lesions...
9.
Lin Z, Zhu Y, Johnson D, Rice K, Nottoli T, Hains B, et al.
Mol Pharmacol
. 2007 Oct;
73(1):243-51.
PMID: 17959714
Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the MRP/ATP-binding cassette family serving as a transmembrane transporter involved in energy-dependent efflux of anticancer/antiviral nucleotide agents and of physiological...